Ophthalmology. Retina
November 2023

Macular Neovascularization type influence on anti-VEGF intravitreal therapy outcomes in Age-related Macular Degeneration

Jordi Izquierdo-Serra, Ruben Martin-Pinardel, Aina Moll-Udina, Carolina Bernal-Morales, Gonzaga Garay-Aramburu, Jorge Sanchez-Monroy, Carolina Arruabarrena, Ana Fernandez-Hortelano, Marta S Figueroa, Maximino Abraldes, Francisco Javier Lavid de Los Mozos, Miguel Angel Zapata, Jose Maria Ruiz-Moreno, Laura Broc-Iturralde, Jacobo Gonzalez-Guijarro, Jose Juan Escobar-Barranco, Roberto Gallego-Pinazo, Alba Parrado-Carrillo, Marina Dotti-Boada, Socorro Alforja, Marc Figueras-Roca, Daniel Barthelmes, Mark C Gillies, Ricardo P Casaroli-Marano, Javier Zarranz-Ventura; Fight Retinal Blindness Spain (FRB! Spain) Users Group


Purpose: To evaluate the influence of macular neovascularization (MNV) lesion type on 12 months clinical outcomes in treatment-naïve eyes with age-related macular degeneration (nAMD) eyes treated with anti-vascular endothelial growth factor (VEGF) drugs nationwide.

Design: Multicenter national nAMD database observational study.

Subjects: One thousand six-hundred six treatment-naïve nAMD eyes (1330 patients) undergoing Anti-VEGF therapy for 12 months nationwide.

Methods: Demographics, visual acuity (VA) in logarithm of the minimum angle of resolution (logMAR) letters, number of injections and visits data was collected using a validated web-based tool. Neovascular lesion phenotype was classified as type 1 (T1, n=711), type 2 (T2, n=505), type 3 (T3, n=315) and aneurysmal type 1 (A-T1, n=75), according to the new proposed consensus classification.

Main outcome measures: Mean VA change at 12 months, final VA at 12 months, number of injections, time to lesion inactivation.

Results: A total of 1606 treatment-naïve nAMD eyes (1330 patients) received a median of 7 injections over 12 months. Mean (±standard deviation) baseline VA was significantly lower for T2 (49.4±23.5 letters) compared to T1 (57.8±20.8) and T3 (58.2 ±19.4)(both p<0.05) lesions. Mean VA change at 12 months was significantly greater for A-T1 (+9.5 letters) compared to T3 (+3.1 letters, p<0.05). T3 lesions had fewer active visits (24.9%) than the other lesion types (T1 30.5%, T2 32.6%, A-T1 27.5%, all p<0.05). Aflibercept was the most used drug in A-T1 lesions (70.1%) and ranibizumab in T1 (40.7%), T2 (57.7%) and T3 (47.6%) lesions. Conclusions: This study highlights the relevance of MNV type on clinical outcomes in nAMD and reports significant differences in baseline VA, VA change and lesion activity at 12 months. This report provides data about lesion-specific clinical features, which may guide the management of nAMD cases and potentially support a personalized clinical decision making in these patients. Keywords: Age-related Macular degeneration; aflibercept; audit; benchmark standard; bevacizumab; neovascular AMD; outcome; ranibizumab; subtype.